Quorum Review IRB has been awarded full reaccreditation for another three years by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
AAHRPP accredits organizations that can demonstrate they provide participant safeguards that surpass the threshold of state and federal requirements. The accreditation program utilizes a voluntary, peer-driven review and educational model.
Through the accreditation process, organizations must demonstrate that they have built extensive safeguards into every level of their research operation and that they adhere to the highest standards for research. AAHRPP’s standards exceed federal regulations by requiring organizations to address conflicts of interest, to provide community outreach and education, and to apply the same stringent protections to all research involving human participants.
Quorum Review was initially awarded full accreditation status from AAHRPP in April of 2006. Accredited organizations are required to renew their accreditation with AAHRPP every three years to demonstrate compliance with current AAHRPP criteria.
Since the last review by AAHRPP in 2006, Quorum has made several changes to its service offerings, including reviewing studies in Canada. Because of these changes, AAHRPP applied the Canadian Tri-Council Policy Statement guidelines in addition to U.S. guidelines in reviewing Quorum’s processes. Quorum is now one of only a few AAHRPP-accredited IRBs that is specifically accredited to review studies in Canada as well as the United States.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.